Skip to content
Menu

Sera Prognostics, Inc. SERA

Full chart Compare
Set alert

Price alert · SERA

All alert types
1.81 USD -0.08 (-4.23%)

Regular-session close

1.81 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

1.80 Day range 1.87
1.59 52-week range 3.69
YTD
-38.64%
1 year
-42.17%

 

No chart data for this range yet.
Market cap
71.98M
Revenue (ttm)
94.00K
EPS (ttm)
-0.67
Shares out
32.80M
Forward P/E
-16.23
YTD return
-38.64%
1-year return
-42.17%
Volume
94.60K
Avg volume
26.59K
Open
1.82
Previous close
1.89
Day's range
1.80 – 1.87
52-week range
1.59 – 3.69
Beta
1.04

Key statistics

50-day average
7.31
200-day average
7.94
Enterprise value
247.87M
Price / sales
3089.82
Price / book
5.31
Revenue growth
-31.00%
Free cash flow
-5.26M
Total cash
49.75M
Total debt
1.10M
Return on equity
-49.58%
Short % of float
3.13%

Fundamental scorecard

8 of 25 checks passed on SERA’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SERA Revenue — quarterly 42.00K
SERA Net income — quarterly -8.05M
SERA EPS — quarterly -0.16

Earnings

SERA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 6, 2024Sep 1, 2024-0.22-0.24-0.02-9.09%
Aug 7, 2024Jun 1, 2024-0.23———
Aug 7, 2024Jun 1, 2024-0.23-0.25-0.02-8.70%
May 8, 2024Mar 1, 2024-0.23———
May 8, 2024Mar 1, 2024-0.23-0.25-0.02-8.70%
Mar 20, 2024Dec 1, 2023-0.25-0.250.000.00%

Upgrades / downgrades

SERA analyst upgrades and downgrades
DateFirmActionFromTo
Aug 10, 2023CitigroupmainNeutralNeutral
Nov 10, 2022Citigroupmain—Neutral
Aug 29, 2022Oppenheimermain—Outperform
Apr 27, 2022Berenberginit—Buy
Mar 30, 2022CitigroupdownBuyNeutral
Nov 19, 2021Oppenheimerinit—Outperform

About Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on SERA — it syncs with the Stock Master app.

Insider holders

SERA insider holders
InsiderRelationLatest transactionDateShares held
AERTS AUSTINChief Financial OfficerSaleDec 9, 2024285,756
BONIFACE JOHN JOfficerSaleNov 10, 2024125,120
CRITCHFIELD GREGORY CDirectorStock Award(Grant)Jun 5, 2024807,270
HARRISON ROBERT GARDNERChief Technology OfficerSaleNov 10, 2024131,046
JACKSON BENJAMIN RGeneral CounselSaleNov 10, 2024135,528
KEARNEY PAULOfficerSaleNov 10, 2024176,889

Institution ownership

SERA institution ownership
Holder% heldSharesValueReported
Baker Bros. Advisors, LP16.57%5,434,39946.74MSep 29, 2024
RA Capital Management, L.P.9.25%3,032,80826.08MSep 29, 2024
Vivo Capital, LLC5.03%1,650,44014.19MSep 29, 2024
Blackrock Inc.4.70%1,540,28113.25MSep 29, 2024
Vanguard Group Inc3.66%1,199,50910.32MSep 29, 2024
JP Morgan Chase & Company2.70%884,8677.61MSep 29, 2024

Fund ownership

SERA fund ownership
Holder% heldSharesValueReported
iShares Russell 2000 ETF2.13%697,6216.00MOct 30, 2024
Vanguard Total Stock Market Index Fund2.09%684,4125.89MSep 29, 2024
Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF1.76%578,7264.98MSep 29, 2024
JP Morgan U.S. Small Company Fund1.04%341,5232.94MSep 29, 2024
Fidelity Small Cap Index Fund0.86%283,0822.43MAug 30, 2024
Vanguard Extended Market Index Fund0.85%279,2232.40MSep 29, 2024